Brainstorm cell therapeutics to unveil phase 3b nurown® trial design at mda clinical and scientific conference

Planned phase 3b trial designed to confirm efficacy and safety  of nurown in mild-to-moderate als patients new york , feb. 27, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#m201) outlining the proposed design for a phase 3b trial of nurown® in amyotrophic lateral sclerosis (als) at the mda clinical and scientific conference, on monday, march 4 between 6-8 p.m. at the hilton orlando hotel, florida.
BCLI Ratings Summary
BCLI Quant Ranking